BAY-1797

Research use only, not for human use.

BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects.

BAY-1797 is an orally active and selective P2X4 antagonist (IC50: 211 nM against human P2X4) with anti-nociceptive and anti-inflammatory effects. BAY-1797 displays no or very weak activity on the other P2X ion channels.

——

Animal Model:Female adult C57BL/6N mice (CFA inflammatory pain model)Dosage:12.5, 25, 50 mg/kg Administration:p.o.; once Result:Dose-dependently reduced PGE2 concentration in inflamed paw.Animal Model:Rat male Wistar Dosage:1 mg/kg Administration:i.v. (Pharmacokinetic Analysis)Result:The AUCnorm, Vss and t1/2 were 1.06 kg h/L, 3.67 L/kg and 2.64 hours, respectively.

——

Neuroscience

P2 Receptor

human P2X4|human P2X1|human P2X23|human P2X3|human P2X7

——

——

2055602-83-8

416.88

C20H17ClN2O4S

>98% (HPLC)

DMSO:250 mg/mL (599.69 mM; Need ultrasonic)

C1=CC=C(C=C1)CC(=O)NC2=CC(=C(C=C2)OC3=CC(=CC=C3)Cl)S(=O)(=O)N

——

(-20℃)

With Ice Pack

≥ 2 years